It is estimated that by 2020, Asia-Pacific will be the second largest market for healthcare technology. CWC offers med-tech companies aspiring to enter that Chinese market comprehensive solutions, from access strategies, expert opinion, fulfilling regulatory obligations, obtaining SFDA approvals, providing local manufacturing capabilities, creating nations-wide distribution networks, as well as governmental and private investment opportunities.
CWC has a network of partners in Beijing, Tianjin, Chengdu, Shanghai and other power centers in China that have the knowledge, governmental relations, and operational capabilities to serve med-tech companies and tele-med companies to launch, approve and distribute their products across China.
CWC has the knowledge and relationships to guide and support our clients through the approval process of the Chinese State Food and Drug Administration (SFDA).
The comprehensive CWC model for market entries enables our clients to receive SFDA approval quickly and launch their products country-wide. The resources of all CWC Divisions become an integrative support network for our clients.
CWC will facilitate between, and accompany, our clients and the Chinese partners with an emphasis on result driven solutions for both parties, foreign and domestic.
In China, CWC advises on procurement of medical technology from overseas, negotiates on behalf of our clients and facilitates acquisition procedures.
There has been an error.
We apologize for any inconvenience, please return to the home page or use the search form below.